|
|
Volumn 10, Issue 1, 2011, Pages 12-13
|
|
The patent cliff steepens
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ATORVASTATIN;
BAPINEUZUMAB;
CLOPIDOGREL;
DONEPEZIL;
ENOXAPARIN;
ESCITALOPRAM;
GENERIC DRUG;
IMMUNOGLOBULIN G;
OLANZAPINE;
PIOGLITAZONE;
QUETIAPINE;
ROSIGLITAZONE;
SOLANEZUMAB;
WARFARIN;
DRUG;
ARTICLE;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG FORMULATION;
DRUG INDUSTRY;
DYSLIPIDEMIA;
ECONOMIC ASPECT;
EXPIRATION DATE;
HEALTH CARE COST;
HUMAN;
PATENT;
POLICY;
PRIORITY JOURNAL;
TREATMENT INDICATION;
ECONOMICS;
LEGAL ASPECT;
UNITED STATES;
DRUG INDUSTRY;
DRUGS, GENERIC;
HUMANS;
PATENTS AS TOPIC;
PHARMACEUTICAL PREPARATIONS;
UNITED STATES;
|
|
EID: 78650846239
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3356 Document Type: Article |
|
Times cited : (48)
|
|
References (0)
|
